🇺🇸 FDA
Patent

US 10376525

Treprostinil administration by inhalation

granted A61KA61K31/192A61K31/557

Quick answer

US patent 10376525 (Treprostinil administration by inhalation) held by United Therapeutics Corporation expires Mon Aug 08 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
United Therapeutics Corporation
Grant date
Tue Aug 13 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 08 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
4
CPC classes
A61K, A61K31/192, A61K31/557, A61K9/0078, A61K9/008